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ABSTRACT
Background: Intravascular ultrasound (IVUS) provides a sensitive 
and reproducible measurement of the coronary artery dimen-
sions, atherosclerotic plaque, and arterial lumen. Advances 
in IVUS technology now allow for the characterisation of 
the composition and morphology of atherosclerotic plaques. 
Although previous studies have reported data using IVUS with 
radiofrequency analysis, little is known regarding the use of a 
new modality (iMap®, Boston Scientific – Santa Clara, CA, USA) 
of atherosclerotic plaque characterisation. This study aims to 
analyse the morphological, phenotypic, and tissue characteristics 
of ‘culprit’ and ‘non-culprit’ atherosclerotic plaques determined 
by angiography in patients undergoing coronary angiography 
due to acute myocardial infarction (AMI). Methods: This will 
be a prospective, cross-sectional, single centre study (Hospital 
São Paulo – Escola Paulista de Medicina – Universidade Federal 
de São Paulo/UNIFESP, São Paulo, SP, Brazil). Fifty patients 
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Study Design
RESUMO
Estudo iWONDER (Imaging WhOle vessel coroNary 
tree with intravascular ultrasounD and iMap®  
in patiEnts with acute myocaRdial infarction):  
Racional e Desenho do Estudo
Introdução: O ultrassom intracoronário (USIC) é um método 
capaz de fornecer medida sensível e reprodutível das di-
mensões da artéria coronária, da placa aterosclerótica e do 
lúmen arterial. Avanços em sua tecnologia permitem agora 
a caracterização da composição e da morfologia das placas 
ateroscleróticas. Embora estudos prévios tenham reportado 
dados utilizando USIC com análise de radiofrequência, o 
uso de uma nova modalidade (iMap®, Boston Scientific, 
Santa Clara, Estados Unidos) de ca racterização da placa 
aterosclerótica é muito pouco conhecida. Nosso objetivo 
será analisar as características morfológicas, teciduais e 
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will be selected for the ultrasound analysis according to the 
following inclusion criteria: age <  75 years, non-ST-segment 
elevation AMI or recent ST-segment elevation AMI, and with 
or without previous fibrinolytic agents. Conclusions: This 
study aims to obtain the morphological, phenotypical, and 
tissue characteristics of the atherosclerotic plaque using an 
imaging modality that has not been extensively evaluated in 
patients with AMI.
 
 
 
 
 
 
 
DESCRIPTORS: Coronary artery disease. Acute coronary syndrome. 
Ultrasonography.
T he angiogram of the coronary artery is a two-dimensional image of the silhouette of the arte-rial lumen from a vascular, three-dimensional, 
complex structure. This test has many well-documented 
limitations,1,2 including the shortening of the vessel, 
overlapping images, and intra-and interobserver vari-
abilities during the analysis of the injury severity; it 
also has considerable limitations in the diagnosis of 
the atherosclerotic plaque composition. However, an 
intravascular ultrasound (IVUS) provides a sensitive and 
reproducible measurement of the dimensions of the 
vessel, atherosclerotic plaque, and arterial lumen. The 
usefulness of greyscale IVUS as a prognostic tool and 
as a guide in percutaneous coronary intervention (PCI) 
is already well established.3,4 More recently, IVUS has 
also generated new insights into the safety and efficacy 
of drug-eluting stents. Advances in IVUS technology now 
allow for the characterisation of the composition and 
morphology of atherosclerotic plaques. Specifically, the 
analysis of the frequency of IVUS waves, in addition to 
the interpretation of the wavelengths used in greyscale 
IVUS, allows for the in vivo analysis of the atheroscle-
rotic plaque composition with high levels of sensitivity 
and specificity.5 Although previous studies have reported 
data using IVUS with radiofrequency analysis,6 little is 
known about the use of a new modality (iMap®, Boston 
Scientific – Santa Clara, CA, USA) for the characterisation 
of the atherosclerotic plaque. Furthermore, the analysis 
and comparison of the lesions known as ‘culprit’ and 
‘non-culprit’ using iMap® in the same patient has also 
been little studied.7–9
This study aims to analyse the morphological, tissue, 
and phenotypical characteristics of the atherosclerotic 
plaques angiographically considered to be ‘culprit’ and 
fenotípicas das placas ateroscleróticas consideradas angio-
graficamente “culpadas” e “não culpadas” em pacientes 
submetidos a angiografia coronária decorrente de infarto 
agudo do miocárdio (IAM). Métodos: Estudo prospectivo, 
transversal, em único centro (Hospital São Paulo – Escola 
Paulista de Medicina – Universidade Federal de São Paulo/
UNIFESP, São Paulo, SP, Brasil). Serão selecionados 50 
pacientes para análise ultrassonográfica, de acordo com 
os seguintes critérios de inclusão: idade < 75 anos, IAM 
sem supradesnivelamento do segmento ST ou IAM com 
supradesnivelamento do segmento ST recente, com ou sem 
uso de fibrinolítico prévio. Conclusões: O presente estudo 
objetivará a caracterização morfológica, tecidual e fenotípica 
da placa aterosclerótica utilizando uma nova modalidade 
de imagem ainda pouco estudada em pacientes com IAM. 
DESCRITORES: Doença da artéria coronária. Síndrome coro-
nária aguda. Ultrassonografia.
‘not-culprit’ in patients undergoing coronary angiogra-
phy due to acute myocardial infarction (AMI) with or 
without ST segment elevation.
METHODS
Study design and patient selection
The study will be conducted as a prospective cross-
sectional, single centre (Hospital São Paulo – Escola 
Paulista de Medicina – Universidade Federal de São 
Paulo/UNIFESP, São Paulo, SP, Brazil) study. A total of 
50 patients will be consecutively selected for ultrasound 
assessment according to the following inclusion criteria: 
age <  75 years, AMI without ST-segment elevation and 
AMI with recent ST-segment elevation, and with or without 
the prior use of fibrinolytics. This selection is based on 
the coronary anatomy and the presence of at least one 
lesion characterised by angiography as an ‘acute plaque’ 
or ‘culprit lesion’ by symptoms in one of the major 
epicardial arteries, as well as the presence of at least 
one ‘non-culprit’ lesion (≥  30% by visual estimation) in 
the other two major epicardial arteries unrelated to the 
event. The exclusion criteria will be the presence of 
haemo dynamic instability, ventricular dysfunction after 
myocardial infarction (Killip class III/IV), lesion in the 
left main coronary artery, angiographic findings of a 
coronary anatomy with significant tortuosity or significant 
proximal calcification, very severe coronary obstruction 
blocking the passage of the IVUS catheter, total occlu-
sion of any of the three epicardial coronary arteries, 
and patients previously submitted to coronary artery 
bypass graft (CABG). The procedures will be performed 
according to the guidelines of the Brazilian Society of 
Cardiology (Sociedade Brasileira de Cardiologia – SBC) 
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and the American Heart Association (AHA).10,11 All 
patients or legal guardians will have to read and sign 
an informed consent. The study was approved by the 
Ethics Committee of UNIFESP (protocol #0889/11) and is 
registered at ClinicalTrial.org (protocol #NCT01437553). 
The schedule provides for the inclusion of patients up 
to the first semester of 2012.
Diagnostic or therapeutic procedure
Initially, an angiography will be performed after the 
intracoronary injection of 200–300 μcg of nitroglycerine. 
When considered appropriate, the IVUS of the three 
epicardial coronary arteries (left anterior descending 
artery, circumflex artery, and right coronary artery) will 
be performed using a 40 MHz IVUS catheter (Atlantis 
SR Pro, Boston Scientific – Santa Clara, CA, USA), with 
greyscale analysis and morphological tissue characteri-
sation using the iMap® software. Automatic retreats of 
the ultrasound catheter will be performed at a velocity 
of 0.5 mm/s, starting at a point > 10 mm distal to the 
‘culprit’ lesion toward the ostium of the analysed artery. 
In the ‘non-culprit’ arteries, the same routine will be 
performed for the analysis of the plaques unrelated to 
the event. Finally, according to the ultrasonographic 
and angiographic findings and based on the clinical 
and electrocardiographic data, the surgeons will de-
cide, together with the cardiologist responsible for the 
patient, on the treatment option to be adopted (clinical 
treatment, surgical revascularisation, or percutaneous 
revascularisation).
A ‘culprit’ lesion will be defined as the coronary 
obstruction that the angiography shows as having cha-
racteristics of instability, such as ulceration, irregular 
borders and eccentricity, luminal thrombus, blurred 
density of the atherosclerotic plaque or significant ob-
struction of the diameter in a compatible artery, and 
related to the ischaemic area in the electrocardiogram 
or echocardiogram.
Analysis by greyscale IVUS and by iMap®
The ultrasound images obtained will be recorded for 
later analysis and offline interpretation through QIvus® 
software (release 2.1, Medis Medical Imaging Systems 
– Leiden, the Netherlands) in the research laboratory of 
invasive imaging analysis of the Hospital Albert Einstein 
(São Paulo, SP, Brazil). The ‘culprit’ and ‘non-culprit’ 
atherosclerotic lesions will be identified. The lesion 
definition is based on the finding of three consecutive 
frames at the IVUS with a plaque burden ≥  40%. The 
lesion will be considered a single lesion if the interval 
between two or more lesions (plaque burden ≥  40%) 
is <  10  mm. The proximal and distal references will 
be set from the finding of the coronary segment with a 
plaque burden < 40% in the 5 mm proximal and distal 
to the lesion. ‘Culprit’ and ‘non-culprit’ lesions will be 
those identified by angiography. For these lesions to be 
identified on the IVUS, reproducible landmarks will be 
adopted both in the angiography and IVUS (e.g., ostium 
vessel, side branch, calcium, and pericardium) to help 
with the analysis reproduction. The following measure-
ments will be performed with the greyscale IVUS: area 
of the external elastic membrane, arterial lumen area, 
vessel diameter, vessel lumen diameter, plaque burden, 
lesion length, minimal luminal area, and total volume 
of the vessel of the lumen and of the atheroma. The 
remodelling index is calculated by the lesion external 
elastic membrane area divided by the area of the external 
elastic membrane of the main reference. Positive remod-
elling will be defined as a remodelling index >  1.05, 
negative remodelling as a remodelling index <  0.95, 
and intermediate remodelling as a remodelling index 
between 0.95 and 1.05.12 The plaque burden is defined 
as the plaque area normalised to the vessel area. Then, 
the quantification of the percentage of the total plaque 
area and cross-sectional area of the following histological 
characteristics by iMap® will be performed (Figure 1): 
1) fibrous tissue (light green), 2) fibroadipose tissue 
(yellow), 3) necrotic core (red), and 4) dense calcium 
(blue). After the quantification of the plaque composi-
tion, the lesions will be phenotypically classified as 
follows: 1) pathological intimal thickening, 2) fibrotic, 
3) fibrolipidic, 4) thick-cap fibroatheroma, and 5) thin-
cap fibroatheroma (vulnerable plaque by iMap®).13,14 
This phenotypic classification will be performed in a 
hierarchical manner. In lesions with multiple phenotypic 
patterns, the most severe will be selected according to 
the following hierarchical relationship: thin-cap fibro-
atheroma, thick-cap fibroatheroma, fibrotic plaque, 
fibrocalcified plaque, and pathological intimal thickening. 
Figure 1 – Examples of several types of atherosclerotic plaque compositions. 
In A, the predominance of fibrous and necrotic tissue (fibroatheroma with 
a thick fibrous cap, in which the necrotic core occupies 27% of the total 
plaque area). In B, the predominance of necrotic tissue with a significant 
calcification area between the 8 and 10 o’clock positions. Between the 
11 and 7 o’clock positions, the plaque is mostly occupied by necrotic 
tissue in contact with the vessel lumen (fibrous thin-cap fibroatheroma). In 
C, the fibronecrotic tissue with calcification is observed at the 3 o’clock 
position. In D, predominantly fibrotic tissue. In E, fibronecrotic tissue 
with calcification spots. In F, fibrotic tissue with significant calcification 
between the 12 and 6 o’clock positions. In G and H, the predominance 
of fibronecrotic tissue (fibroatheromas).
A
E
B
F
C
G
D
H
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IVUS TECHNOLOGY TO EVALUATE PLAQUE 
COMPOSITION
The main cause of AMI is the rupture or erosion of 
an atherosclerotic plaque with superimposed thrombus 
formation.15 Histopathologically, the type of plaque 
more prone to rupture is the thin-cap fibroatheroma,13 
characterised by a thin fibrous cap richly infiltrated by 
macrophages and covering a large necrotic core with 
neovascularisation. This fibroatheroma in the pre-rupture 
phase is called a vulnerable plaque. Alternatively, a 
clinical definition of a vulnerable plaque would be 
an atherosclerotic lesion that places the patient at 
greater risk for future adverse cardiovascular events. 
The identification of a vulnerable plaque before its 
clinical presentation is a great challenge, but it offers 
the potential benefit of guiding preventive therapy in a 
large number of patients who develop acute coronary 
syndrome. Notably, most vulnerable plaques that trig-
ger future events have an obstruction < 50%, both on 
angiography and histopathology assessments.16
The greyscale IVUS derived from the analysis of the 
intravascular ultrasound signal amplitude is commonly 
used for the quantitative analysis of the atheroma, such 
as lesion length, vessel diameter, plaque burden, steno-
sis severity, and lumen dimensions, and is a useful tool 
to guide PCIs with stent implanting. The morphologic 
characteristics of ‘culprit’ lesions on the greyscale IVUS 
are variable and may include an echolucent core, eccen-
tricity, positive remodelling, ulceration, thrombosis, and 
calcification.17 Recently, the presence of an attenuated 
plaque on the greyscale image has been correlated with 
microcalcification, thrombus, or cholesterol crystals.18,19 
This situation has been more predominantly observed in 
patients with acute coronary syndrome than in patients 
with stable angina,20 and in situations that trigger the 
no-reflow phenomenon (absence or marked reduction 
in coronary flow after angioplasty, in the absence of a 
residual stenotic lesion) or increase in the creatine kinase 
MB fraction after PCI.21,22 However, the greyscale IVUS 
is unable to identify the histomorphological character-
istics associated with plaque rupture and vulnerability, 
including thin-cap fibroatheroma.
Variations in the traditional greyscale IVUS tech-
nique will allow for a more detailed characterisation of 
the atherosclerotic plaque tissue. Among the available 
options, the most widespread are virtual histology (VH® 
IVUS, Volcano Therapeutics, Inc. – Rancho Cordova, 
CA, USA) and, more recently, the characterisation of 
the atherosclerotic plaque using the iMap® software. The 
technology using VH® IVUS has been studied in patients 
with acute coronary syndrome6,7 and in analyses evaluating 
the regression and progression of atherosclerotic plaques 
associated with various therapeutics, such as statins.23,24
The Providing Regional Observations to Study 
Predictors of Events in the Coronary Tree (PROSPECT) 
study6 is the largest prospective study evaluating the 
natural history of coronary artery disease to date. This 
study, involving 697 patients undergoing VH® IVUS, was 
designed to correlate the histological characteristics of 
the lesions, patient risk factors, and other measurements 
(clinical and laboratory) with subsequent cardiac events. 
After a mean follow-up of 3.4 years, lesions considered 
to be ‘culprit’ (those initially treated after the initial 
acute coronary syndrome) and ‘non-culprit’ lesions 
(lesions considered mild to moderate on angiography, 
which were not treated initially) were responsible for 
similar rates of the primary composite endpoint of 
cardiac death, AMI, and unstable or progressive angina 
(12.9% vs. 11.6%, respectively). The main predictors 
correlating ‘non-culprit’ lesions to the primary endpoint 
were diabetes with insulin use, plaque burden ≥ 70%, 
presence of a plaque morphologically classified as a 
thin-cap fibroatheroma, and a minimal lumen area 
≤  4  mm2. Thus, the authors were able to conclude 
that the prospective identification and characterisation 
of ‘non-culprit’ lesions in the coronary arteries with 
virtual histology are predictors of adverse cardiovascular 
events over the subsequent 3 years.
In the ‘VH-IVUS in Vulnerable Atherosclerosis (VIVA)’ 
study,25 using the VH® IVUS technology, 170 patients with 
stable angina or acute coronary syndrome referred for 
PCI were prospectively enrolled and submitted to pre-
intervention IVUS of the three epicardial coronary vessels. 
In total, 30,372 mm of IVUS were analysed with virtual 
histology. A total of 18 major cardiovascular events (i.e., 
death, AMI, or non-planned revascularisation) occurred 
in 16 patients after a mean follow-up of 625 days; 1,096 
lesions were identified, with 19 resulting in events (13 
‘non-culprit’ and six ‘culprit’ lesions). The risk factors as-
sociated with ‘non-culprit’ lesions that resulted in major 
cardiovascular events were, as in the PROSPECT study, 
the presence of a thin-cap fibroatheroma, plaque burden 
≥  70%, and minimal lumen area ≤  4 mm2.
Detailed studies of the phenotypic and tissue com-
position of the atherosclerotic plaques in patients with 
acute coronary syndrome using the iMap® mapping are 
still scarce. Offline analysis with the iMap® software 
allows for the interference of calcium or guidewire 
artefacts mistakenly classified as calcium (pseudocal-
cification) to be attenuated or even negated (Figure 2). 
Figure 2 – Examples of two types of pseudocalcification determined by 
the presence of calcium (A and B) and a guidewire (C and D). In A, 
the presence of a calcium arc between the 3 and 7 o’clock positions 
prevents the passage of ultrasound waves; the tissue interpretation is thus 
wrongly classified as necrotic tissue. In C, the artefact of the guidewire 
can be noticed within 12 hours. In B and D, the offline analysis software 
allows for the minimization of the calcium and guidewire artefacts.
A B C D
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Thus, mapping by iMap® has potential advantages 
compared with other technologies available for the 
characterisa tion of atherosclerotic plaques and for the 
better understanding of the physiopathology of AMI. 
CONCLUSIONS
This study will aim to perform the morphologic, 
tissue, and phenotypic characterisation of the athero-
sclerotic plaque using a new imaging modality, which 
has been scarcely studied in patients with AMI.
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